1. BAD clinical re-audit on isotretinoin Audit contributorsBAD members, with some contributions from non-members LeadsDavid de Berker, Tak Cheung and M Firouz Mohd Mustapa Audit standards source BAD isotretinoin audit standards Data Members were requested to enter relevant data for the last three consecutive patients (including at least one male and one female) who had completed treatment with isotretinoin for acne vulgaris within the last 6 months. Completion date2014 Number of contributors 338 responses (7 unidentified) from 179 identifiable hospitals [221 responses in 2012] Number of patients1013 total; 992 when broken down by region [663 total in 2012] Published Exton L.S., Cheung S.T., Brain A, Mohd Mustapa M.F., de Berker, D Compliance with isotretinoin national guidelines – where are we 2 years since the last audit? BAD Newsl 2014, 17 (4) 26-9.

2. Breakdown of the 338 participants by region

3. Q1. Was the patient seen in a monitoring clinic* for patients on systemic treatment? (*any clinic specifically for monitoring patients receiving systemic therapies)

4. Q2. Did female patients of childbearing potential receiving isotretinoin sign the ‘acknowledgement of PPP information’ form indicating that they received appropriate information? Boxplots showing the distributional mean percentage of “Yes” responses

5. Q4. Did female patients in the pregnancy prevention programme have pregnancy tests before treatment and at monthly intervals through treatment? Boxplots showing the distributional mean percentage of “Yes” responses

6. Q5. Did female patients in the pregnancy prevention programme have a pregnancy test five weeks after completing treatment? Boxplots showing the distributional mean percentage of “Yes” responses

7. 96 Number of female patients on PPP having recorded a pregnancy test five weeks after completing treatment, by type of clinic (total number of patients involved are indicated for each response in each setting).

8. Q3. Did all patients have serum lipids checked prior to starting treatment and at least once during treatment? Boxplots showing the distributional mean percentage of “Yes” responses

9. Q7. Was there documentation of mental health and/or mood state for all patients on isotretinoin, both at the assessment for treatment and on follow-up? Boxplots showing the distributional mean percentage of “Yes” responses